A Phase Ib/II Open-label Study Evaluating Safety and Efficacy of Oral BKM120 in Combination With Lapatinib in HER2+/PI3K-activated, Trastuzumab-resistant Locally Advanced, Recurrent and Metastatic Breast Cancer. PIKHER2/IPC 2011-001

Trial Profile

A Phase Ib/II Open-label Study Evaluating Safety and Efficacy of Oral BKM120 in Combination With Lapatinib in HER2+/PI3K-activated, Trastuzumab-resistant Locally Advanced, Recurrent and Metastatic Breast Cancer. PIKHER2/IPC 2011-001

Suspended
Phase of Trial: Phase I/II

Latest Information Update: 23 Sep 2017

At a glance

  • Drugs Buparlisib (Primary) ; Lapatinib
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PIKHER2
  • Most Recent Events

    • 23 Sep 2017 Results (n=24) assessing buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer, were published in the European Journal of Cancer.
    • 10 Jun 2017 Biomarkers information updated
    • 01 Dec 2015 Planned End Date changed from 1 Sep 2016 to 1 Jan 2018 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top